Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Voyager Therapeutics, Inc.VYGR · Entity 6271 | VP, Finance | March 21, 2022 | March 23, 2022 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Voyager Therapeutics, Inc.
Report date March 21, 2022 · Filed March 23, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 52,458 |
Ending reported balance
After 2022-03-21 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2022-03-21 · Sale · Disposed 2,618 · Balance 52,489 F1: Represents shares of common stock sold, pursuant to a durable automatic sales instruction letter effecting the sell-to-cover election of the reporting person to satisfy tax withholding obligations, in connection with the vesting of restricted stock units on March 19, 2022. The reporting person structured the durable automatic sales instructions to constitute a "binding contract" consistent with the affirmative defense to liability under Rule 10b5-1. The sales do not represent a discretionary trade by the reporting person. F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $7.66 to $8.655, inclusive. The reporting person undertakes to provide to Voyager Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) to this Form 4. Row 2 · 2022-03-21 · Sale · Disposed 31 · Balance 52,458 F1: Represents shares of common stock sold, pursuant to a durable automatic sales instruction letter effecting the sell-to-cover election of the reporting person to satisfy tax withholding obligations, in connection with the vesting of restricted stock units on March 19, 2022. The reporting person structured the durable automatic sales instructions to constitute a "binding contract" consistent with the affirmative defense to liability under Rule 10b5-1. The sales do not represent a discretionary trade by the reporting person. F3: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $8.66 to $8.695, inclusive. The reporting person undertakes to provide to Voyager Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (3) to this Form 4. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents shares of common stock sold, pursuant to a durable automatic sales instruction letter effecting the sell-to-cover election of the reporting person to satisfy tax withholding obligations, in connection with the vesting of restricted stock units on March 19, 2022. The reporting person structured the durable automatic sales instructions to constitute a "binding contract" consistent with the affirmative defense to liability under Rule 10b5-1. The sales do not represent a discretionary trade by the reporting person.
F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $7.66 to $8.655, inclusive. The reporting person undertakes to provide to Voyager Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) to this Form 4.
F3: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $8.66 to $8.695, inclusive. The reporting person undertakes to provide to Voyager Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (3) to this Form 4.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 21, 2022 Filed Mar 23, 2022 18:36 UTC | Voyager Therapeutics, Inc. VYGR · Entity 6271 | SaleCommon Stock | 31 | $8.68 | $269.08 |
DisclosureSEC source: 0001104659-22-037151 · tm2210284-2_4seq1.xml · nonDerivative · entry 2 Burek Julie · CIK 0001894915 · VP, Finance 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 52,458 F1 · kind: Represents shares of common stock sold, pursuant to a durable automatic sales instruction letter effecting the sell-to-cover election of the reporting person to satisfy tax withholding obligations, in connection with the vesting of restricted stock units on March 19, 2022. The reporting person structured the durable automatic sales instructions to constitute a "binding contract" consistent with the affirmative defense to liability under Rule 10b5-1. The sales do not represent a discretionary trade by the reporting person. F1 · shares: Represents shares of common stock sold, pursuant to a durable automatic sales instruction letter effecting the sell-to-cover election of the reporting person to satisfy tax withholding obligations, in connection with the vesting of restricted stock units on March 19, 2022. The reporting person structured the durable automatic sales instructions to constitute a "binding contract" consistent with the affirmative defense to liability under Rule 10b5-1. The sales do not represent a discretionary trade by the reporting person. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $8.66 to $8.695, inclusive. The reporting person undertakes to provide to Voyager Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (3) to this Form 4. Read SEC document |
| March 21, 2022 Filed Mar 23, 2022 18:36 UTC | Voyager Therapeutics, Inc. VYGR · Entity 6271 | SaleCommon Stock | 2,618 | $8.29 | $21,703.22 |
DisclosureSEC source: 0001104659-22-037151 · tm2210284-2_4seq1.xml · nonDerivative · entry 1 Burek Julie · CIK 0001894915 · VP, Finance 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 52,489 F1 · kind: Represents shares of common stock sold, pursuant to a durable automatic sales instruction letter effecting the sell-to-cover election of the reporting person to satisfy tax withholding obligations, in connection with the vesting of restricted stock units on March 19, 2022. The reporting person structured the durable automatic sales instructions to constitute a "binding contract" consistent with the affirmative defense to liability under Rule 10b5-1. The sales do not represent a discretionary trade by the reporting person. F1 · shares: Represents shares of common stock sold, pursuant to a durable automatic sales instruction letter effecting the sell-to-cover election of the reporting person to satisfy tax withholding obligations, in connection with the vesting of restricted stock units on March 19, 2022. The reporting person structured the durable automatic sales instructions to constitute a "binding contract" consistent with the affirmative defense to liability under Rule 10b5-1. The sales do not represent a discretionary trade by the reporting person. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $7.66 to $8.655, inclusive. The reporting person undertakes to provide to Voyager Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) to this Form 4. Read SEC document |
| February 17, 2022 Filed Feb 22, 2022 16:35 UTC | Voyager Therapeutics, Inc. VYGR · Entity 6271 | SaleCommon Stock | 789 | $3.55 | $2,800.95 |
DisclosureSEC source: 0001104659-22-025669 · tm227228-1_4seq1.xml · nonDerivative · entry 1 Burek Julie · CIK 0001894915 · VP, Finance 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 55,107 F1 · kind: Represents shares of common stock sold, pursuant to a durable automatic sales instruction letter effecting the sell-to-cover election of the reporting person to satisfy tax withholding obligations, in connection with the vesting of restricted stock units on February 16, 2022. The reporting person structured the durable automatic sales instructions to constitute a "binding contract" consistent with the affirmative defense to liability under Rule 10b5-1. The sales do not represent a discretionary trade by the reporting person. F1 · shares: Represents shares of common stock sold, pursuant to a durable automatic sales instruction letter effecting the sell-to-cover election of the reporting person to satisfy tax withholding obligations, in connection with the vesting of restricted stock units on February 16, 2022. The reporting person structured the durable automatic sales instructions to constitute a "binding contract" consistent with the affirmative defense to liability under Rule 10b5-1. The sales do not represent a discretionary trade by the reporting person. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $3.49 to $3.67, inclusive. The reporting person undertakes to provide to Voyager Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) to this Form 4. Read SEC document |
| February 11, 2022 Filed Feb 15, 2022 16:40 UTC | Voyager Therapeutics, Inc. VYGR · Entity 6271 | SaleCommon Stock | 361 | $3.36 | $1,212.96 |
DisclosureSEC source: 0001104659-22-023833 · tm226802-1_4seq1.xml · nonDerivative · entry 1 Burek Julie · CIK 0001894915 · VP, Finance 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 55,896 F1 · kind: Represents shares of common stock sold, pursuant to a durable automatic sales instruction letter effecting the sell-to-cover election of the reporting person to satisfy tax withholding obligations, in connection with the vesting of restricted stock units on February 10, 2022. The reporting person structured the durable automatic sales instructions to constitute a "binding contract" consistent with the affirmative defense to liability under Rule 10b5-1. The sales do not represent a discretionary trade by the reporting person. F1 · shares: Represents shares of common stock sold, pursuant to a durable automatic sales instruction letter effecting the sell-to-cover election of the reporting person to satisfy tax withholding obligations, in connection with the vesting of restricted stock units on February 10, 2022. The reporting person structured the durable automatic sales instructions to constitute a "binding contract" consistent with the affirmative defense to liability under Rule 10b5-1. The sales do not represent a discretionary trade by the reporting person. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $3.30 to $3.43, inclusive. The reporting person undertakes to provide to Voyager Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) to this Form 4. Read SEC document |
| January 13, 2022 Filed Jan 18, 2022 20:06 UTC | Voyager Therapeutics, Inc. VYGR · Entity 6271 | GrantStock Option (Right to Buy) · Derivative | 40,000 | $0.00 Strike: $2.85 | $0.00 |
DisclosureSEC source: 0001104659-22-005023 · tm223208-3_4seq1.xml · derivative · entry 2 Burek Julie · CIK 0001894915 · VP, Finance 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,000 Underlying: Common Stock · 40,000 shares Expires 2032-01-13 F2 · derivative.exercise_date: This stock option was issued pursuant to the Plan. The vesting commencement date of the option is the grant date, January 13, 2022. The option vests over four years, with 1/48th of the shares of common stock underlying the option vesting upon the one-month anniversary of such vesting commencement date and an additional 1/48th of the shares of common stock underlying the option vesting at the end of each successive one-month period thereafter, subject to the Reporting Person's continued service. Read SEC document |
| January 13, 2022 Filed Jan 18, 2022 20:06 UTC | Voyager Therapeutics, Inc. VYGR · Entity 6271 | GrantCommon Stock | 10,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-22-005023 · tm223208-3_4seq1.xml · nonDerivative · entry 1 Burek Julie · CIK 0001894915 · VP, Finance 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 56,257 F1 · shares: Consists of shares of common stock issuable under an aggregate of 10,000 restricted stock units ("RSUs") awarded to the Reporting Person pursuant to the Voyager Therapeutics, Inc. 2015 Stock Option and Incentive Plan (the "Plan"). Each RSU represents the right to receive one share of common stock upon vesting. The vesting commencement date of the RSU award is the grant date, January 13, 2022. The RSU award vests over three years, with 1/3rd of the shares of common stock underlying the RSU award vesting on the one-year anniversary of such vesting commencement date and an additional 1/3rd of the shares of common stock underlying the RSU award vesting at the end of each successive one-year period thereafter, subject to the Reporting Person's continued service. Read SEC document |
| January 12, 2022 Filed Jan 14, 2022 18:14 UTC | Voyager Therapeutics, Inc. VYGR · Entity 6271 | SaleCommon Stock | 265 | $3.06 | $810.90 |
DisclosureSEC source: 0001104659-22-004515 · tm223086-1_4seq1.xml · nonDerivative · entry 3 Burek Julie · CIK 0001894915 · VP, Finance 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 46,257 F2 · kind: Represents shares of common stock sold, pursuant to a durable automatic sales instruction letter effecting the sell-to-cover election of the reporting person to satisfy tax withholding obligations, in connection with the vesting of restricted stock units on January 11, 2022. The reporting person structured the durable automatic sales instructions to constitute a "binding contract" consistent with the affirmative defense to liability under Rule 10b5-1. The sales do not represent a discretionary trade by the reporting person. F2 · shares: Represents shares of common stock sold, pursuant to a durable automatic sales instruction letter effecting the sell-to-cover election of the reporting person to satisfy tax withholding obligations, in connection with the vesting of restricted stock units on January 11, 2022. The reporting person structured the durable automatic sales instructions to constitute a "binding contract" consistent with the affirmative defense to liability under Rule 10b5-1. The sales do not represent a discretionary trade by the reporting person. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $2.92 to $3.22, inclusive. The reporting person undertakes to provide to Voyager Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (3) to this Form 4. Read SEC document |
| January 03, 2022 Filed Jan 14, 2022 18:14 UTC | Voyager Therapeutics, Inc. VYGR · Entity 6271 | SaleCommon Stock | 3,063 | $2.83 | $8,668.29 |
DisclosureSEC source: 0001104659-22-004515 · tm223086-1_4seq1.xml · nonDerivative · entry 2 Burek Julie · CIK 0001894915 · VP, Finance 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 46,522 Read SEC document |
| December 31, 2021 Filed Jan 14, 2022 18:14 UTC | Voyager Therapeutics, Inc. VYGR · Entity 6271 | GrantCommon Stock | 3,063 | $2.30 | $7,044.90 |
DisclosureSEC source: 0001104659-22-004515 · tm223086-1_4seq1.xml · nonDerivative · entry 1 Burek Julie · CIK 0001894915 · VP, Finance 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 49,585 F1 · kind: Represents shares acquired under the Voyager Therapeutics, Inc. 2015 Employee Stock Purchase Plan in a transaction that was exempt under both Rule 16b-3(c) and Rule 16b-3(d). F1 · shares: Represents shares acquired under the Voyager Therapeutics, Inc. 2015 Employee Stock Purchase Plan in a transaction that was exempt under both Rule 16b-3(c) and Rule 16b-3(d). Read SEC document |
| November 26, 2021 Filed Nov 30, 2021 16:34 UTC | Voyager Therapeutics, Inc. VYGR · Entity 6271 | GrantStock Option (Right to Buy) · Derivative | 25,000 | $0.00 Strike: $3.06 | $0.00 |
DisclosureSEC source: 0001104659-21-144995 · tm2134192-2_4seq1.xml · derivative · entry 2 Burek Julie · CIK 0001894915 · VP, Finance 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2031-11-26 F2 · derivative.exercise_date: This stock option was issued pursuant to the 2015 Plan. The vesting commencement date of the option is the grant date. The option vests over four years, with 1/48th of the shares of common stock underlying the option vesting upon the one-month anniversary of the option's vesting commencement date and an additional 1/48th of the shares of common stock underlying the option vesting at the end of each successive one-month period thereafter, subject to the Reporting Person's continued service. Read SEC document |
| November 26, 2021 Filed Nov 30, 2021 16:34 UTC | Voyager Therapeutics, Inc. VYGR · Entity 6271 | GrantCommon Stock | 13,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-21-144995 · tm2134192-2_4seq1.xml · nonDerivative · entry 1 Burek Julie · CIK 0001894915 · VP, Finance 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 46,522 F1 · shares: Consists of shares of common stock issuable under restricted stock units ("RSUs") awarded to the Reporting Person pursuant to the Voyager Therapeutics, Inc. 2015 Stock Option and Incentive Plan (the "2015 Plan"). Each RSU represents the right to receive one share of common stock upon vesting. The vesting commencement date of the RSU award is January 1, 2022. The RSU award vests over three years, with 1/3rd of the shares of common stock underlying the RSU award vesting on the one-year anniversary of such vesting commencement date and an additional 1/3rd of the shares of common stock underlying the RSU award vesting at the end of each successive one-year period thereafter, subject to the Reporting Person's continued service. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.